UK NEQAS for General Haematology is the expert centre within UK NEQAS for all aspects of General Haematology diagnostic testing external quality assessment (EQA). The Scheme provides EQA for automated haematology counting, blood and bone marrow morphology, haemoglobinopathies and other inherited red cell disorders.

UK NEQAS Haematology offers a wide range of related EQA schemes from which participants may select the combination that fits their laboratory profile. This makes the Scheme flexible and adaptable to participants’ needs. UK NEQAS Haematology serves over 1300 participants, with approximately 750 laboratories and other pathology service providers in the UK and a further 600 internationally.

All UK NEQAS Haematology services comply with the UK NEQAS Charity’s Code of Practice and are offered on a not-for-profit basis.

UK NEQAS Haematology, on behalf of the World Health Organization (WHO), also organises an International EQA Scheme (IEQAS Haematology) which has been designed mainly for developing countries. IEQAS Haematology has nearly 80 participants in over 50 countries.

Purpose

This programme is designed for users of automated haematology analysers providing full blood count (FBC or CBC) data in clinical, veterinary, research, pharmaceutical and health surveillance settings. The survey material is suitable for all the major analyser models.

Point of care testing analysers are accommodated in this programme, either in the full blood count (FB) option, or in the haemoglobin only (HB) option, depending on the parameters supplied by the instrument.

Analytes and units
Analyte Units
White blood count (WBC) 109/L
Haemoglobin (Hb) g/L
Red blood count (RBC) 10^12/L
Haematocrit (Hct) L/L
Mean cell volume (MCV) fL
Mean cell haemoglobin (MCH) pg
Mean cell haemoglobin (MCH) pg
Mean cell haemoglobin concentration (MCHC) g/L
Platelet count (PLT) 10^9/L
Programme design

Full blood count (FB) option: Two whole blood specimens are issued per distribution, with 12 distributions per year on a monthly basis (24 specimens per year). All participants receive the same material type, although instruments are grouped for performance analysis. The specimens are prepared from pooled human blood donations (collected from individually consented donors by the UK NHS Blood and Transplant Service), partially fixed and treated with antibiotics. Haemoglobin concentration, red blood count, white blood count and platelet count are varied to test performance at levels of clinical decision making. Participants may register up to 3 instruments for a single fee, with an additional fee for each instrument above 3. A single set of survey material is dispatched for multiple analysers. Point of care instruments that provide a full blood count result, i.e. more than a haemoglobin result, may register in this scheme.

Hb only (HB) option: Participants with point of care instruments that only produce a haemoglobin result are registered in the Hb only option of the scheme. Two whole blood specimens are provided 12 times per year. The specimens are treated with antibiotics but not stabilised. Participants may register up to 3 instruments for a single fee, with an additional charge for each instrument above 3. A single set of specimens is dispatched for each analyser, making this option convenient for analysers in multiple point of care testing locations.

Both options are performance monitored for participation and analytical performance, for all the parameters listed.

Instrument groups available

The instrument groupings available are shown in table 3 in the Performance Scoring section. The Scheme Office can supply the most up to date list of instrument groups.

Purpose

This programme is designed to complement the Full Blood Count programme for any participant who offers an automated differential count as part of their extended full blood count.

Analytes and units
  • Three or five population differential leucocyte count, as performed using an automated haematology analyser. NRBC’s are included for selected analysers.
Analyte Units
White Cell Count 10^9/L
Neutrophils [LCR/LCC, Gran#, GR#] g/L
Lymphocytes [SCR/SCC, LYMP#, LY#] 10^9/L
Monocytes [MCR/MCC, MID#, MO#, MONO#] 10^9/L
Eosinophils# 10^9/L
Basophils# 10^9/L
LUC# 10^9/L
NRBC# 10^9/L
Programme design

Two specimens of commercially prepared whole blood material are distributed, six times per year (12 specimens per year). Ten types of commercially prepared survey material are available, and the choice of material type (matrix) is instrument dependent. Analysis of results is by material type and in some cases by individual instrument type. Table 2 lists the matrices that are distributed, and the instruments covered by each matrix. The information in table 2 is a guide only and the scheme office can provide the most up to date information on availability of the programme for particular analysers. Participants may register up to 3 instruments for a single fee, with an additional fee for each instrument above 3. A single set of survey material is dispatched for multiple instruments; where a participant registers analysers that require different matrices, these are supplied at no additional cost.

Purpose

This programme is designed as a supplement to the Full Blood Count scheme for laboratories that prepare therapeutic blood components. The scheme supplies specimens for haemoglobin concentration, haematocrit and platelet count at the levels found in blood components, beyond the normal physiological ranges.

Analytes and units
Analyte Units
Haemoglobin (Hb) g/L
Haematocrit (Hct) L/L
Platelet count (PLT) 10^9/L
Programme design

Four distributions, each containing 2 red cell specimens for haemoglobin/haematocrit and 2 platelet concentrate specimens for platelet count, are made each year. Red cell specimens are not stabilised but are treated with antibiotics. Platelet concentrate specimens are fully fixed. Participants may register up to 3 analysers or modes of analysis, for a single fee.

The programme is performance monitored for participation and analytical performance, for all the parameters listed. Performance is monitored in a single instrument group.

Purpose

This programme is designed for the performance monitoring of reticulocyte counting by automated analysers.

Analytes and units
Analyte Units
Reticulocyte count 10^9/L
Programme design

Two whole blood specimens are distributed six times per year (12 specimens per year). Survey specimens are either commercially produced material or partially stabilised material produced by UK NEQAS Haematology. Beckman Coulter LH series analysers require a separate survey material (Matrix X). Participants may register up to 3 instruments for a single fee, with an additional fee for each instrument above 3. A single set of survey material is dispatched for multiple instruments.

The programme is performance monitored for participation and analytical performance. Performance monitoring for automated counting methods is by instrument group.

Purpose

This programme monitors the performance of plasma Viscocity.

Analytes and units
Analyte Units
Plasma Viscocity mPas
Programme design

Two specimens of plasma are distributed 12 times per year (24 specimens per year). Survey material is prepared from donated plasma surplus to that required for therapeutic use. The Viscocity of the plasma is manipulated, and the material treated with antibiotics and an antifungal.

Analysis of results is by all methods and by instrument group, where there are sufficient instruments available. Participants may register up to 3 instruments for a single fee.

The programme is monitored for participation and analytical performance. Performance is monitored against all methods and instrument group, where sufficient instruments are registered.

Purpose

This programme is designed to maintain and improve skills in blood film morphology, manual differential counting and blood parasite identification. Participation is by organisation. Participants may opt out of blood parasite identification, if this is not a service that is offered as part of their clinical repertoire; however, many sites in this situation choose to remain in this part of the scheme for educational purposes. The fee is the same, whatever the level of participation.

Analytes
  • Peripheral blood films (with occasional bone marrow films) for the identification of significant morphological features (BF slides)
  • A manual differential count on selected blood films (DF surveys). Results are returned as both percentage and absolute counts
  • A pilot option for differential count by Automated Cell Imaging Systems. Results are returned for pre and post verification percentage and absolute counts
  • Peripheral blood films for the detection and identification of blood parasites (PA slides)
  • A parasitaemia count (%) if Plasmodium falciparum or Plasmodium knowlesi is present
Programme design

Two blood films for morphology comments are distributed eight times per year (16 BF slides per year). A WBC differential is requested on four of the BF slides each year (4 DF cases per year). Two blood films for blood parasite identification are distributed four times per year (8 PA slides per year). Films for morphology are fixed in methanol and stained with May-Grünwald-Giemsa; films for parasite identification are fixed in methanol or acetone and stained as appropriate for the specific parasite.

The programme is monitored for participation, gross errors of morphological identification, blood parasite detection and species identification and percent parasitaemia counting (Plasmodium falciparum and Plasmodium knowlesi infections). DF surveys are reported in summary format only, without individual participant performance assessment.

Purpose

This programme is designed to monitor the performance of iron staining and assessment for bone marrow and urinary haemosiderin.

Analytes
  • Iron staining (Perls’ stain) – programme under redesign
  • Digital images for assessment of stained iron
Scheme design

Two distributions of either bone marrow, peripheral blood or urine deposits, or are issued per year as digital images for assessment and interpretation of iron status. Participants are asked to score the strength of the staining reaction and to report the presence of sideroblasts.

The distribution of slides for participants to stain for the assessment of Perl’s staining technique is under development.

The programme is monitored for participation. The analytical results are reported to participants for self-assessment purposes.

Purpose

This programme is designed to monitor the performance of the erythrocyte sedimentation rate (ESR).

Analytes and units

Erythrocyte sedimentation rate (ESR) in mm per hour

Programme design

The programme is offered in two modules: ES and ESX.

The ES module is suitable for sedimentation methods based on the Westergren method. Four distributions of 2 commercially produced, whole blood specimens are provided each year. Instruments and methods are grouped for performance analysis.

The ESX module is suitable for latex-based methods (Alifax instruments). Four distributions of 3 commercially produced, latex specimens are provided each year. Performance is reported separately from the ES module.

Participants may register as many instruments as they wish in either module and the fee charged is based upon the module and the number of instruments.

The programme is monitored for participation and analytical performance.

Purpose

This programme is designed to assess the performance of rapid diagnostic tests for malaria detection. It is operated in collaboration with UK NEQAS Parasitology and is offered to UK NEQAS Haematology participants registered for the Blood Films scheme.

Analytes
  • Species specific malarial antigen in blood
Programme design

Participants may register more than one kit method but must identify the results generated from each kit registered.

Two specimens of lysed whole blood containing recombinant malarial antigen are distributed 4 times a year, with each distribution of Blood Films for Parasite Identification. Results are returned as positive or negative with speciation if positive, dependent on the kit used.

The programme is monitored for participation and analytical performance.

Purpose

This scheme is designed to assess the performance of non-molecular detection techniques in the screening and diagnostic testing for the haemoglobinopathies, using liquid blood specimens. There are 3 options for participation:

  • Option 1: Sickle screening only (SS specimens), for participants who perform a qualitative sickle screening test (e.g. sickle solubility testing or other similar technique) only. This is not suitable for laboratories using a quantitative method to detect Hb S (e.g. HPLC or CE).
  • Option 2: Full participation (SS and AH specimens), for participants who undertake qualitative sickle screening and haemoglobin variant detection and identification (adult specimens), fraction quantification and interpretation. Full participation includes the qualitative sickle screening option, for participants who undertake this test.
  • Option 3: Full participation plus the liquid capillary specimens for newborn haemoglobinopathy screening option (SS, AH and LN specimens) for participants who undertake the diagnostic testing of newborn infants’ specimens for haemoglobin variants in addition to testing adult specimens.

Participants may register for any or all of the analytes offered; the tariff of fees varies according to the option selected.

Analytes and units
  • Hb variant identification: adult (AH) specimens
  • Hb variant identification: liquid newborn (LN) specimens
  • Detection of Hb S by qualitative sickle screening tests (reported as positive or negative): SS specimens
  • Quantification of Hb A2, Hb F and Hb S (AH) % total Hb
  • Assessment of Hb A2 and Hb F in terms of the participant’s reference range (AH)
  • Interpretation of results (AH and LN)
Scheme design

There are 6 distributions per year of each option. Sickle screening only participants receive 3 specimens in each survey for sickle screening (SS specimens). Full participants receive the specimens for sickle screening, plus an additional 3 specimens (AH specimens) for Hb variant identification using all available methods, including sickle screening, fraction quantification and interpretation. The specimens are prepared by UK NEQAS Haematology, and are accompanied by background details of full blood count, age, gender, ethnic group and clinical condition. The survey material is treated with antibiotics but is not fixed. Participants registered for the liquid capillary newborn specimens (LN) receive an additional 6 specimens per year for haemoglobin variant identification and interpretation.

Participants are monitored for participation, sickle solubility test, Hb A2 measurement and Hb S measurement. Fraction identification (AH or LN specimens), Hb F quantification and interpretation of results are performance assessed but there is no numerical performance score provided at present. Where applicable, performance monitoring is based on the laboratory standards published by the National Sickle and Thalassaemia Screening Programme in England.

Purpose

This scheme is designed to performance assess the screening of dried blood spot cards for clinically significant variant haemoglobins by laboratories that offer newborn sickle screening, either as a primary testing or a confirmatory testing site.

Analytes
  • Identification of sickle haemoglobin and other clinically significant variant haemoglobins
  • Interpretation of results obtained
  • Scheme design

12 distributions are made per year on a monthly basis. Each distribution contains 3 dried blood spot newborn screening cards prepared from EDTA anti-coagulated umbilical cord blood (36 specimens per year). The specimens are suitable for screening by high performance liquid chromatography (HPLC), isoelectric focusing (IEF), capillary electrophoresis (CE) and tandem mass spectrometry (TMS).

Performance is scored for participation, fraction identification and interpretation. The performance monitoring is based on the laboratory standards published by the National Sickle and Thalassaemia Screening Programme in England.

Purpose

This scheme is designed to performance assess the mutational analysis for thalassaemia, with occasional samples for the identification of variant haemoglobins, and the interpretation of the results obtained in context of the patient’s clinical background and other haematology. It is suitable for specialist laboratories that offer molecular haemoglobinopathy testing as part of their diagnostic repertoire.

Analytes
  • Mutational analysis for alpha and beta thalassaemia, with occasional specimens for variant haemoglobins
  • Interpretation of results obtained
  • Recommendations for follow up
  • Annotation of results making the correct use of the HGVS nomenclature system
Scheme design

Three distributions, each containing 2 specimens, are made per year (6 specimens in total). Survey material is supplied as DNA in TE buffer and is suitable for all molecular haemoglobinopathy techniques. Each specimen is supplied with clinical case details, gender, ethnic background and haematology results.

Participants may register for full participation (alpha and beta thalassaemia mutational analysis) or for alpha or beta thalassaemia mutational analysis only. All receive the same specimens.

Participants are monitored for participation, mutational analysis, interpretation, recommendations for follow up and the use of annotation. Performance is measured against a model answer defined by the scheme with the support of a panel of expert advisors.

Purpose

This scheme is designed for laboratories that perform qualitative screening and/or quantitative assay for the red cell enzyme Glucose-6-phosphate dehydrogenase (G6PD). These surveys do not currently include any other red cell enzymes.

Analytes and units
  • Qualitative screening test
  • Quantitative assay IU/gHb
  • Assessment of quantitation in terms of the participant’s reference range
Scheme design

Six distributions of 2 specimens each are made per year. The specimens are prepared by UK NEQAS Haematology from human whole blood and animal whole blood. The survey material is treated with antibiotics but is not fixed, and is dispensed using the same method as for full blood count specimens. The survey material is suitable for most recognised methods currently available, although variable results have been reported with screening methods based on dye decolourisation. For this reason, this method is not actively performance assessed.

Participants may register for the screening test or the quantitative assay or both. The same fee is charged in all cases. Performance is scored for participation, screening and quantitative assay.

Experimental trials to identify specific sources of error or to test new materials and assay procedures may also be distributed. These experimental trials are distributed as additional, free of charge, surveys usually in the same mailing as the normal surveys. Individual laboratory performance is NOT assessed in these trials.

Participants may be invited to take part in studies as part of larger projects. Participation in these studies is always voluntary.

Some trials may involve the use of questionnaires. Where possible, these are distributed electronically, usually to the main laboratory contact. Again, participation is voluntary. UK NEQAS Haematology greatly appreciates the effort and support of participants in any development work.

Before a new programme is recognised as a full programme, it is operated on a pilot basis. These programmes may or may not be charged for depending upon the degree of development and the availability of alternative sources of funding.

Pilot programmes are not formally performance assessed and out of consensus performance is reported to the participant only, for information.

UK NEQAS Haematology offers pilot schemes in development for:
  • Pyruvate Kinase
  • POCT WBC Differential
  • Retic Hb Content
Parasitology Teaching

The Parasitology Teaching day is offered in conjunction with the UK NEQAS Parasitology Scheme. The day covers all aspects of blood parasite identification and each participant receives a teaching manual and set of teaching slides to keep. The participant fee covers up to two members of staff. Teaching sessions are offered at a variety of locations throughout the UK and Republic of Ireland during the year. Once registered, you will be offered a place at the geographical location closest to your organisation.

Location

The Scheme is hosted by the West Hertfordshire Hospitals NHS Trust and is based at Watford General Hospital, in a Unit shared with UK NEQAS (H) and (FMH)

Contact the Scheme Office (see above) and request a registration pack

Between January and March of each year, participants are contacted and asked to confirm their re-registration details for the following financial year on-line.

Alterations to your instrument or method details, should be sent to us in writing either by letter or via email. The letter can be sent from a named contact but must also be signed off or cc’d with the head of the laboratory or laboratory manager. The Main contact will get the opportunity to update the method & Instrument details via the Re-Registration process online. The Main contact will be notified when the Re-registration process will become available to allow them to make the changes themselves. Any changes must be received at least 3 weeks before the scheduled distribution date to be effective for that distribution.

Please contact the Scheme Office for a copy of the current fees sheet or a quotation.

This is a 5 digit, unique reference number that is issued when you register and should be quoted in all communications with the Scheme.

Laboratory managers can register a group of staff for Digital Morphology when registering or re-registering for other UK NEQAS (H) services. Individual practitioners should register via www.ukneqash.org, following the links to the Digital Morphology home page.

Specimen packages should be received within 2 days of dispatch for participants in the UK. Outside the UK, courier delivery usually takes up to 4 – 5 days.

Please contact the Scheme Office and request a replacement specimen pack.

Repeat specimens are generally available throughout the survey period to replace specimens received in an unsatisfactory condition (i.e. broken, leaking, unlabelled, haemolysed or clotted) and to replace those accidentally damaged or misplaced in the laboratory. Specimens may be neither available nor suitable for analysis after the survey has closed. Please contact the Scheme office for availability of repeat specimens.

If you are unable to return your results by the closing date, you may submit them late subject to certain conditions. Web Users should contact the Scheme for results sheets for those surveys using the Web Results Service or download a blank results form from the data entry website. If you use a blank form, remember to include you participant reference number (PRN). The first report you receive may not show your results, but a second ‘late’ report, showing your results, will be generated before the next survey is processed. Unless we have agreed to accept your results late without penalty, you will receive a non-participation score (see Performance Monitoring). Specimens analysed after the closing date may no longer be suitable for analysis and you should contact the scheme office for advice.

A PDF copy of the web entry instructions is available for download from the documents section of the website (www.ukneqash.org).

In the case of forgotten login details, please see here for the instructions how to reset your password.


Please note that the password is case sensitive, and the password to log onto our website is the same as the web entry page.

To change your web entry password, please see here for the instructions how to change your password online.

If you realise you have made an error in your on-line submission or you submit an incomplete set of results, contact us directly. We are able to reset your data entry page until the closing date, allowing you to resubmit your results.

This usually occurs because data has been submitted late or not at all, or has not been received. If you know you have returned your results in time, contact the Scheme immediately.

Results are generally loge transformed before calculating statistics, this includes the calculation of DI value. It is not possible to calculate the SD from the GCV using the usual formula.

These are available to download from the documents section of the Scheme web-site (www.ukneqash.org)

For the JWG Conditions of Participation please visit : RCPATH QAPC

Only participants with a current, active licence can access open cases. Ensure you have activated your licence. If not, see your lab manager to obtain the activation key.

Contact the UK NEQAS (H) Scheme office to verify your email address is on the database.

Contact the UK NEQAS (H) Scheme office or click on the ‘forgotten password’ link from the Digital Morphology home page.

You can register staff for the Parasitology Teaching Day with your other UK NEQAS (H) services, at re-registration. Contact the UK NEQAS (H) Scheme office if you wish to register at other times or you wish to register additional staff. Registration at other times is subject to availability of places.

Only the main contacts are allowed to edit and create contact details. Please see here for the instructions how to create/edit contact details online.

Date Updated Description
UK NEQAS Compendium of Quality 20-11-2018 10:06
Terms and Conditions 17-08-2021 14:18
Terms and Conditions for Digital Services 23-12-2019 15:23 Digital Services
UK NEQAS Haematology Participants' Manual 18-01-2024 11:46
EQATE Users' Manual 19-10-2023 10:38
Date Updated Description
What does UKAS expect from Quality Assurance? Martin Stearn 13-11-2023 11:49 UK NEQAS Haematology 24th Annual Participants' Meeting, 10.10.23
Morphology, mistakes & AI - John Burthem 13-11-2023 11:54 UK NEQAS Haematology 24th Annual Participants' meeting, 10.10.23
Malaria diagnosis: blood films, rapid diagnostic tests & the emergence of P. falciparum HRP2 - Debbie Nolder 13-11-2023 12:09 UK NEQAS Haematology 24th Annual Participants' meeting, 10.10.23
Haemoglobinopathy Cases 1-4 - Barbara Bain, Mel Proven, Jason Eyre, Clare Samuelson 13-11-2023 14:31 UK NEQAS Haematology 24th Annual Participants' meeting, 10.10.23
A most interesting Haemoglobinopathy (Case 5) - Bashori Rahman 13-11-2023 13:04 UK NEQAS Haematology 24th Annual Participants' meeting, 10.10.23
Interpretation of true iron deficiency - Wayne Thomas 13-11-2023 14:33 UK NEQAS Haematology 24th Annual Participants' meeting, 10.10.23
UK NEQAS Haematology Annual Meeting 2019 Ms Yvonne John - UK NEQAS Developments 13-01-2020 14:29
UK NEQAS Haematology Annual Meeting 2019 Ms Carol Stearn - Measurement Uncertainty 13-01-2020 14:29
UK NEQAS Haematology Annual Meeting 2019 Mr Martin Stearn - ISO 15189 Preparation for Reassessment 13-01-2020 14:29
UK NEQAS Haematology Symposium 2018 Yvonne John - UK NEQAS Developments 16-10-2019 10:34
UK NEQAS Haematology Annual Meeting 2019 Mr David Bloxham - The laboratory diagnosis of Lymphoma 13-01-2020 14:30
UK NEQAS Haematology Annual Meeting 2019 Dr Paula Bianchi - Investigating the Haemolytic Patient 13-01-2020 14:30
UK NEQAS Haematology Annual Meeting 2019 Dr Mike Leach, Dr Peter Carey, Professor Barbara Bain, Dr John Burthem - My Favourite Film 13-01-2020 14:30
UK NEQAS Haematology Annual Meeting 2019 Dr John Burthem and Mr Jon Sims - Morphology and more - the EQATE Digital Platform 13-01-2020 14:30
UK NEQAS Haematology Annual Meeting 2019 Dr Barbara De la Salle - So my performance is satisfactory 13-01-2020 14:30
UK NEQAS Haematology Symposium 2018 John Burthem and Jon Sims - Digital Morphology Platform Launch - past, present and future 13-01-2020 14:31
UK NEQAS Haematology Annual Meeting 2019 Mr Liam Whitby - UK NEQAS at 50 13-01-2020 14:36
UK NEQAS Haematology Symposium 2018 Dr Jennifer Eglinton - The Sickle and Thalassaemia Helpline: What have we learned? 13-01-2020 14:32
UK NEQAS Haematology Symposium 2018 Dr Yvonne Daniel - Mistakes in Haemoglobinopathy Diagnosis - Incidents in the Screening Programme 13-01-2020 14:32
UK NEQAS Haematology Symposium 2018 Professor Barbara Bain - The Neglected Red Cell 13-01-2020 14:32
UK NEQAS Haematology Symposium 2017 Dr Samuel Boadi - Attending a UK NEQAS Blood Parasitology Teaching Programme 16-10-2019 10:33
UK NEQAS Haematology Symposium 2017 Alun Roderick - UK NEQAS Automated Counting focus 16-10-2019 10:33
UK NEQAS Haematology Symposium 2014 Perspective on performance: The Haemoglobinopathies - Barbara Wild 13-01-2020 14:32
UK NEQAS Haematology Symposium 2017 Nina Gade Christensen - EQA in POCT: the Norwegian experience 16-10-2019 10:33
UK NEQAS Haematology Symposium 2018 Dr Barbara De la Salle - Mistakes in Haemoglobinopathy Diagnosis - Haemoglobinopathy EQA 13-01-2020 14:32
UK NEQAS Haematology Symposium 2017 Dr Barbara Wild - UK NEQAS Haemoglobinopathy focus: Where are the mistakes made? 16-10-2019 10:33
UK NEQAS Haematology Symposium 2017 Dr John Burthem - UK NEQAS Morphology focus 16-10-2019 10:33
UK NEQAS Haematology Symposium 2018 Professor Peter Chiodini - Parasitology Diagnosis 13-01-2020 14:33
UK NEQAS Haematology Symposium 2017 Professor Barbara Bain - The role of blood film morphology in thrombocytopenia and platelet disorders 13-01-2020 14:33
UK NEQAS Haematology Symposium 2017 Barbara De la Salle - A ‘Compendium of Quality’ 16-10-2019 10:33
UK NEQAS Haematology Symposium 2016 Helen Verrill - Driving quality improvement 16-10-2019 10:33
UK NEQAS Haematology Symposium 2017 Dr Wayne Thomas - Laboratory diagnosis of iron deficiency: The interpretation of automated counting parameters 13-01-2020 14:33
UK NEQAS Haematology Symposium 2017 Dr Julian Barth - ‘So…is my result normal?’ 13-01-2020 14:33
UK NEQAS Haematology Symposium 2016 Jon Sims - Morphology Focus - Performance Assessment 16-10-2019 10:33
UK NEQAS Haematology Symposium 2017 Yvonne John - UK NEQAS: My first seven months 13-01-2020 14:33
UK NEQAS Haematology Symposium 2016 Barbara De la Salle - Mind the EQA Gap 16-10-2019 10:33
UK NEQAS Haematology Symposium 2016 Dr Barbara Wild - Haemoglobinopathies Focus - Learning from EQA 16-10-2019 10:33
UK NEQAS Haematology Symposium 2016 Dr John Burthem - Quality assuring remote diagnostics 16-10-2019 10:33
UK NEQAS Haematology Symposium 2016 Dr Keith Gomez - Action on unsatisfactory performance 16-10-2019 10:33
UK NEQAS Haematology Symposium 2016 Dr Yvonne Daniel - National Screening Programmes: support, education and oversight 16-10-2019 10:32
UK NEQAS Haematology Symposium 2015 Dr Mike Cornes Garbage in Garbage out - errors outside the analytical phase.pdf 04-01-2019 14:42
UK NEQAS Haematology Symposium 2015 Dr William McKane Critical results Management - the Clinicians view.pdf 04-01-2019 14:42
UK NEQAS Haematology Symposium 2016 Professor Angela Thomas - Haemophilia - from man to dog to man 16-10-2019 10:32
UK NEQAS Haematology Symposium 2014 Poster - Uncertainty 04-01-2019 14:40
UK NEQAS Haematology Symposium 2016 Susanne Kricke - Automated Counting Focus - MPV and RDW EQA 16-10-2019 10:31
UK NEQAS Haematology Symposium 2014 Why do we make mistakes in morphological diagnosis – how can we improve? - John Burthem 04-01-2019 14:40
UK NEQAS Haematology Symposium 2014 Progress in the Laboratory Diagnosis of Red Cell Membrane Disorders - May-Jean King 04-01-2019 14:39
UK NEQAS Haematology Symposium 2015 Dr Michael Devlin Critical results management - The medico-legal view.pdf 16-10-2019 10:31
UK NEQAS Haematology Symposium 2015 Ian Mellors UK NEQAS Automated Counting update.pdf 16-10-2019 10:31
UK NEQAS Haematology Symposium 2014 The sex difference in haemoglobin levels in adults - Mechanisms, causes and consequences - William G. Murphy 04-01-2019 14:39
UK NEQAS Haematology Symposium 2014 Feedback & Directions - Ian Mellors 04-01-2019 14:39
UK NEQAS Haematology Symposium 2015 Kate Ryan Case study - When critical results reporting can go wrong.pdf 16-10-2019 10:31
UK NEQAS Haematology Symposium 2015 Mrs Tracey Smith-Straney Critical Results Management - The laboratory view .pdf 16-10-2019 10:31
UK NEQAS Haematology Symposium 2014 HEE the big picture and its relevance to HCS - Prof. Ian Cumming 04-01-2019 14:39
UK NEQAS Haematology Symposium 2014 ICSH Guidelines Verification and Performance of Automated Cell Counters for Body Fluids Counting - Barbara De la Salle 04-01-2019 14:39
UK NEQAS Haematology Symposium 2015 Professor Neil Dalton The application of TMS.pdf 16-10-2019 10:31
UK NEQAS Haematology Symposium 2014 Pathology Quality Review : Outcomes and Update - Dr Ian Barnes 04-01-2019 14:38
UK NEQAS Haematology Symposium 2015 Barbara De la Salle - How do you define a critical result.pdf 16-10-2019 10:31
UK NEQAS Haematology Symposium 2015 Carol D Souza New POC technology in blood counting.pdf 13-01-2020 14:35
Date Updated Description
Blood Parasite teaching sheets on the UK NEQAS Parasitology website 02-01-2019 11:14
UK NEQAS Haematology Instructions for using the web results service (PDF) 17-05-2022 11:51
Blood Film Comment Codes 17-05-2022 11:53
HS Digital Instructions 11-01-2023 14:47
MN result sheet 09-03-2023 15:30 Infectious Mononucleosis programme result sheet
CM result sheet 09-03-2023 15:31 Blood Component Monitoring programme result sheet
DNA instructions for data entry 09-06-2023 14:49 Instructions for DNA participants on how to submit their results using the website
UK NEQAS CM_Instructions for data entry 17-08-2023 13:52
UK NEQAS MN_Instructions for data entry 17-08-2023 13:55
Date Updated Description
UK NEQAS Haematology Newsletter (PDF) 06-08-2019 14:36
UK NEQAS Haematology Wish List For Blood Films Morphology Cases (PDF) 06-08-2019 14:36
GH Newsletter 2022 08-02-2022 09:16 GH Newsletter 2022
GH Newsletter 2024 13-02-2024 09:08
Date Updated Description
Programme Flyer UK NEQAS POCT Event 30th June 2022 26-04-2022 11:07 Programme Flyer_UK NEQAS POCT Event 30th June 2022
Parasitology Teaching Day 12-02-2024 15:25
Date Updated Description
Vial Changes Field Notice 24-05-2022 08:52